• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br factors for developing endometrial cancer


    404 factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol.
    407 Absolute risk of endometrial carcinoma during 20-year follow-up among women with
    410 the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials.
    416 11.Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of
    417 serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet
    419 12.Pejic S, Todorovic A, Stojiljkovic V, Kasapovic J, Pajovic SB. Antioxidant enzymes and
    420 lipid peroxidation in MK-571 sodium salt hydrate of patients with polyps, myoma, hyperplasia and
    423 Activities of antioxidant enzymes and lipid peroxidation in endometrial cancer. Eur J Cancer.
    426 amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer.
    431 role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer
    434 of multimarker panel for early detection of endometrial cancer. High diagnostic power of
    437 Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung,
    442 reliable serum biomarker for discriminating high-risk endometrial cancer. Tumour Biol.
    445 prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial
    448 Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    451 antigen 9 is a promising marker for early diagnosis of endometrial cancer. Asian Pac J Cancer
    454 associated antigen 9 in patients with endometrial carcinoma. Int J Gynecol Cancer.
    456 25.Konno R, Takano T, Sato S, Yajima A. Serum soluble fas level as a prognostic factor in
    463 preoperative CA 125 level in the management of uterine cancer and prediction MK-571 sodium salt hydrate of clinical
    467 Table 1. Demographic Characteristics of Endometrial Cancer Cases and Matched Controls
    Cases Controls
    Age (at randomization)b
    Body Mass Index (kg/m2)
    Number of Live Births
    Highest Education Level Attained
    Menopausal Hormone Use
    Smoking Status
    469 a P values based on c2 statistics 470 b Matching factors. Other matching factors not included in the table are study center, year of randomization, and 471 year of blood draw; there was no statistical difference in distribution between cases and controls 472 473
    474 475 476 Table 2. Significantly Altered Proteins among Cases versus Controls ≤ 2 Years to Diagnosis
    478 *10 proteins significantly different between cases and controls ≤ 2 years of diagnosis and also showing same rate of 479 change in concentration of protein over three time categories
    480 **Paired Limma adjusted by serum albumin protein abundance
    482 Figure Legends
    483 484 Figure 1. Study selection process. 485 486 Figure 2. Prioritization of protein alterations with high diagnostic potential. Among cases where
    487 blood draw occurred ≤ 2 years of endometrial cancer diagnosis, there are 47 proteins
    488 significantly altered between cases and controls (P<0.05). Comparative analyses of these
    489 abundance trends for cases diagnosed > 2 years to ≤ 5 years with matched controls and > 5 years
    490 with matched controls resulted in the prioritization of ten protein candidates reflecting identical
    491 abundance trends as observed in cases diagnosed within 2 years from blood draw. Six high-
    492 confidence candidates were selected from the ten by LASSO regression analysis; figure depicts
    493 case versus control abundance trends for these six candidates in patients diagnosed with
    495 496 Figure 3. A serum-based, integrated risk score to predict endometrial cancer. Protein alterations
    497 with high diagnostic potential were selected by LASSO regression analysis and assembled into
    498 an aggregate score calculated for each case to predict the relative risk of having endometrial
    499 cancer. A: Integrated risk scores are directly related to disease incidence in patients with blood
    501 Integrated risk scores exhibit a linear relationship from time of blood draw to receiving a
    502 diagnosis of endometrial cancer.
    504 Figure 4. Evaluation of a serum-based, integrated risk score to predict endometrial cancer.
    505 Receiver operator curve evaluating integrated score for 6 high-confidence proteins (complement
    506 factor B, serotransferrin, catalase, proteasome subunit beta type-6, beta-2-microglobulin, and